SpeeDx Announces Agreement with Goffin Molecular Technologies
News Apr 05, 2016
SpeeDx Pty, Ltd. has announced a distribution agreement with Goffin Molecular Technologies B.V. The agreement will open new channels for SpeeDx’ PlexPCR™ and unique ResistancePlus™ multiplex real time polymerase chain reaction (qPCR) product lines to the Benelux market (Belgium, Netherlands and Luxembourg).
“The timing of this agreement aligns well with our near-term European launch plans to offer our PlexPCR infectious disease and ResistancePlus antibiotic resistance multiplex qPCR tests in the Benelux market,” said Colin Denver, Vice President of Sales & Marketing, SpeeDx. “Based on Goffin’s track record, we’re confident that this collaboration will rapidly increase our European presence in targeted molecular diagnostic markets.”
SpeeDx is committed to pioneering multiplex molecular diagnostic solutions to the global antibiotic resistance problem by offering tests that not only identify infectious disease pathogens but provide actionable information on the antimicrobial resistance status of the pathogen. SpeeDx is initially focusing its ResistancePlus pipeline on sexually transmitted infections (STIs) such as Mycobacterium genitalium (MG) and Neisseria gonorrhoeae (NG) since both organisms have large and rapidly growing antibiotic resistance challenges.
Goffin Molecular Technologies offers a comprehensive line of molecular diagnostic products in the areas of infectious diseases, genetics, automation, consumables, reagents, instruments and pre-analytical treatments. Goffin’s qPCR kit for the determination of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) is the company’s most successful assay in Europe.
“We see our relationship with SpeeDx strengthening our core strategy as we continue to focus on new market needs,” said Eric van Vught, Director of Sales, Goffin Molecular Technologies.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019